Investors reposed faith in our future growth prospects: Syngene
Readying to list its shares after a bumper 32-times over-subscribed IPO, biotechnology major Biocon's research arm Syngene on Thursday said the investors have reposed faith in its future growth prospects.
Jul 30, 2015, 16:51 PM IST